Trevi Therapeutics, Inc. (TRVI)
NASDAQ$6.29
Market Cap
$562.11M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
886 of 925
Rank in Industry
504 of 528
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
TRVI Insider Trading Activity
TRVI Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $1,119,351 | 15 | 100 |
Related Transactions
| Delfini Lisa | Chief Financial Officer | 0 | $0 | 1 | $11,485 | $-11,485 |
| Meeker David P | director | 0 | $0 | 1 | $13,353 | $-13,353 |
| SCIASCIA THOMAS | Chief Scientific Officer | 0 | $0 | 5 | $272,220 | $-272,220 |
| GOOD JENNIFER L | President & CEO | 0 | $0 | 7 | $273,416 | $-273,416 |
| Simon Farrell | Chief Commercial Officer | 0 | $0 | 1 | $548,878 | $-548,878 |
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in …
Insider Activity of Trevi Therapeutics, Inc.
Over the last 12 months, insiders at Trevi Therapeutics, Inc. have bought $0 and sold $1.12M worth of Trevi Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Trevi Therapeutics, Inc. have bought $22.8M and sold $388,241 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,631,578 shares for transaction amount of $5M was made by NEA 16 GP, LLC () on 2022‑04‑11.
List of Insider Buy and Sell Transactions, Trevi Therapeutics, Inc.
| 2025-03-10 | Sale | Simon Farrell | Chief Commercial Officer | 81,313 0.1012% | $6.75 | $548,878 | +3.79% | |
| 2024-09-09 | Sale | GOOD JENNIFER L | President & CEO | 1,840 0.0025% | $3.04 | $5,587 | +10.26% | |
| 2024-09-06 | Sale | GOOD JENNIFER L | President & CEO | 4,219 0.006% | $3.03 | $12,784 | +16.10% | |
| 2024-09-05 | Sale | GOOD JENNIFER L | President & CEO | 40,277 0.0557% | $3.11 | $125,310 | +10.00% | |
| 2024-09-04 | Sale | GOOD JENNIFER L | President & CEO | 10,981 0.0155% | $3.02 | $33,205 | +14.92% | |
| 2024-09-03 | Sale | GOOD JENNIFER L | President & CEO | 3,863 0.0054% | $3.02 | $11,677 | +13.47% | |
| 2024-08-27 | Sale | Meeker David P | director | 4,555 0.0063% | $2.93 | $13,353 | +14.78% | |
| 2024-08-19 | Sale | SCIASCIA THOMAS | Chief Scientific Officer | 16,496 0.0227% | $2.96 | $48,883 | +11.11% | |
| 2024-08-16 | Sale | SCIASCIA THOMAS | Chief Scientific Officer | 18,660 0.0268% | $2.76 | $51,440 | +19.13% | |
| 2024-08-15 | Sale | SCIASCIA THOMAS | Chief Scientific Officer | 12,745 0.0185% | $2.79 | $35,513 | +20.00% | |
| 2024-08-14 | Sale | SCIASCIA THOMAS | Chief Scientific Officer | 100 0.0001% | $2.75 | $275 | +26.44% | |
| 2024-05-29 | Sale | SCIASCIA THOMAS | Chief Scientific Officer | 53,368 0.0761% | $2.55 | $136,110 | +22.05% | |
| 2024-05-22 | Sale | Delfini Lisa | Chief Financial Officer | 4,350 0.0062% | $2.64 | $11,485 | +16.23% | |
| 2024-05-20 | Sale | GOOD JENNIFER L | President & CEO | 25,037 0.0359% | $2.86 | $71,576 | +8.83% | |
| 2024-05-10 | Sale | GOOD JENNIFER L | President & CEO | 4,578 0.0069% | $2.90 | $13,276 | +11.36% | |
| 2023-10-11 | Sale | Delfini Lisa | Chief Financial Officer | 785 0.0012% | $2.02 | $1,586 | +32.11% | |
| 2023-09-11 | Sale | Delfini Lisa | Chief Financial Officer | 711 0.0011% | $2.20 | $1,564 | +15.27% | |
| 2023-08-11 | Sale | Delfini Lisa | Chief Financial Officer | 682 0.0011% | $2.36 | $1,610 | -1.05% | |
| 2023-07-11 | Sale | Delfini Lisa | Chief Financial Officer | 687 0.0007% | $2.34 | $1,608 | +0.55% | |
| 2023-06-12 | Sale | Delfini Lisa | Chief Financial Officer | 610 0.0006% | $2.64 | $1,610 | -11.72% |
Total: 75
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Meeker David P | director | 352489 0.3944% | $2.22M | 1 | 1 | <0.0001% |
| GOOD JENNIFER L | President & CEO | 213313 0.2387% | $1.34M | 1 | 7 | <0.0001% |
| BASKETT FOREST | 10421428 11.6616% | $65.55M | 3 | 1 | +1.73% | |
| Makhzoumi Mohamad | 10421428 11.6616% | $65.55M | 3 | 1 | +1.73% | |
| NEA 16 GP, LLC | 10421428 11.6616% | $65.55M | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$36,510,315 | 95 | 8.95% | $600.23M | |
$587,109,125 | 90 | 3.17% | $509.59M | |
$14,527,743 | 76 | 38.40% | $473.67M | |
Trevi Therapeutics, Inc. (TRVI) | $678,065,999 | 37 | -13.32% | $562.11M |
$94,912,877 | 34 | -7.15% | $605.37M |
TRVI Institutional Investors: Active Positions
| Increased Positions | 74 | +98.67% | 28M | +47.62% |
| Decreased Positions | 31 | -41.33% | 6M | -10.48% |
| New Positions | 27 | New | 13M | New |
| Sold Out Positions | 8 | Sold Out | 260,157 | Sold Out |
| Total Postitions | 118 | +57.33% | 80M | +37.14% |
TRVI Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Nea Management Company, Llc | $51,394.00 | 12.78% | 11.37M | 0 | 0% | 2024-12-31 |
| Frazier Life Sciences Management, L.P. | $48,205.00 | 11.98% | 10.66M | +3M | +44.49% | 2024-12-31 |
| Viking Global Investors Lp | $19,888.00 | 4.94% | 4.4M | 0 | 0% | 2024-12-31 |
| Rubric Capital Management Lp | $19,007.00 | 4.72% | 4.21M | -821,802 | -16.35% | 2024-12-31 |
| Point72 Asset Management, L.P. | $18,759.00 | 4.66% | 4.15M | +4M | New | 2024-12-31 |
| Blackrock, Inc. | $17,757.00 | 4.41% | 3.93M | +706,710 | +21.94% | 2024-12-31 |
| Vanguard Group Inc | $15,862.00 | 3.94% | 3.51M | +246,832 | +7.57% | 2024-12-31 |
| Vivo Capital, Llc | $15,765.00 | 3.92% | 3.49M | +2M | +116.25% | 2024-12-31 |
| Woodline Partners Lp | $14,521.00 | 3.61% | 3.21M | +3M | +429.93% | 2024-12-31 |
| Mpm Bioimpact Llc | $13,989.00 | 3.48% | 3.09M | +2M | +101.16% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.